The industry remains under scrutiny because of pricing decisions, pipeline failures, and profit concerns. What can top stocks like Gilead Sciences In this episode of The Motley Fool’s Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to offer up some resolutions they’d like biotech’s C-suite to stick to in 2017.